Medicine recalls
|
| |
| Singapore: Recall of Thymoglobuline 5 mg/ml Powder for Concentrate for Solution for Infusion |
| |
Health Sciences Authority (HSA) announced that Genzyme, a Sanofi Company, is initiating a voluntary recall of 2 lots of Thymoglobuline 5 mg/ml Powder for concentrate for solution for infusion. The lot numbers are C0074 and C0088. The affected lots of Thymoglobuline are being recalled due to the potential risk for a stability failure prior to end of shelf life for aggregation. Healthcare professionals are advised to stop using the Thymoglobuline from the affected lots.
Please refer to the following website in HSA for details:
http://www.hsa.gov.sg/publish/hsaportal/../DHCPL.html
In Hong Kong, Thymoglobuline for IV Injection 25mg/5ml (HK-33039), containing anti-thymocyte immunoglobulins, is registered by Sanofi-Aventis Hong Kong Limited. The Department of Health has endorsed the recall of three affected batches with numbers C0074H29, C0088H10 and C0102H03 of Thymoglobuline for IV Injection 25mg/5ml from the market by Sanofi-Aventis Hong Kong Limited, because of the stability issue. Press release regarding the recall was issued on 3 August 2012. Related news has been released by UK MHRA and was posted on the website of Drug Office on 7 August 2012.
Ends/ Thursday, August 23, 2012
Issued at HKT 16:00 |
| |
|
